Literature DB >> 7376796

Metabolism of a new synthetic progestagen, Org 2969, in female volunteers. The distribution and excretion of radioactivity after an oral dose of the labelled drug.

L Viinikka, O Ylikorkala, R Vihko, H G Hasenack, H Nieuwenhuyse.   

Abstract

The metabolism of a new synthetic progestagen, Org 2969 was studied in 4 healthy female volunteers. During the first part of the study (Phase I), the volunteers ingested 50 microgram (about 0.1 mCi) of [16-3H5Org 2969 together with 50 microgram of ethinyloestradiol as a single dose. During the second part of the study (Phase II), a 10-day pre-treatment with the same dosage of non-radioactive compound preceded the administration of the radioactive steroid. A peak level of total radioactivity, representing 3.16-5.02% of the dose given/l of serum, was achieved within 2-3 h in Phase I. During Phase II, the corresponding figures were 4.54-5.13% after 1.5-3 h. The difference was mainly due to an increase of freely-extractable steroids during Phase II. The difference can at least partly be explained by assuming a change in the kinetics of the metabolism of Org 2969 by pre-treatment with Org 2969 and ethinyloestradiol. The mean recovery of radio activity in urine and faeces was 83.0%/48.1%/34.9% (total/urine/faeces) of the total dose in Phase I and 76.1%/45.2%/30.9% during Phase II. The differences in the total excretion and in the radioactivity excreted in the faeces were significant.

Entities:  

Keywords:  Biology; Clinical Research; Contraception; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents--administraction and dosage; Contraceptive Methods--pharmacodynamics; Family Planning; Human Volunteers; Metabolic Effects; Oral Contraceptives--pharmacodynamics; Physiology; Research Methodology; Steroid Metabolic Effects; Women

Mesh:

Substances:

Year:  1980        PMID: 7376796     DOI: 10.1530/acta.0.0930375

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  2 in total

Review 1.  Mass balance studies, with a focus on anticancer drugs.

Authors:  Jan H Beumer; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Bioavailability and bioequivalence of etonogestrel from two oral formulations of desogestrel: Cerazette and Liseta.

Authors:  C J Timmer; N Srivastava; T O Dieben; A F Cohen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Oct-Dec       Impact factor: 2.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.